The efficacy of tetracyclines in peripheral and intracerebral prion infection
- PMID: 18365024
- PMCID: PMC2268013
- DOI: 10.1371/journal.pone.0001888
The efficacy of tetracyclines in peripheral and intracerebral prion infection
Abstract
We have previously shown that tetracyclines interact with and reverse the protease resistance of pathological prion protein extracted from scrapie-infected animals and patients with all forms of Creutzfeldt-Jakob disease, lowering the prion titre and prolonging survival of cerebrally infected animals. To investigate the effectiveness of these drugs as anti-prion agents Syrian hamsters were inoculated intramuscularly or subcutaneously with 263K scrapie strain at a 10(-4) dilution. Tetracyclines were injected intramuscularly or intraperitoneally at the dose of 10 mg/kg. A single intramuscular dose of doxycycline one hour after infection in the same site of inoculation prolonged median survival by 64%. Intraperitoneal doses of tetracyclines every two days for 40 or 44 days increased survival time by 25% (doxycycline), 32% (tetracycline); and 81% (minocycline) after intramuscular infection, and 35% (doxycycline) after subcutaneous infection. To extend the therapeutic potential of tetracyclines, we investigated the efficacy of direct infusion of tetracyclines in advanced infection. Since intracerebroventricular infusion of tetracycline solutions can cause overt acute toxicity in animals, we entrapped the drugs in liposomes. Animals were inoculated intracerebrally with a 10(-4) dilution of the 263K scrapie strain. A single intracerebroventricular infusion of 25 microg/20 microl of doxycycline or minocycline entrapped in liposomes was administered 60 days after inoculation, when 50% of animals showed initial symptoms of the disease. Median survival increased of 8.1% with doxycycline and 10% with minocycline. These data suggest that tetracyclines might have therapeutic potential for humans.
Conflict of interest statement
Figures


Similar articles
-
Tetracyclines affect prion infectivity.Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10849-54. doi: 10.1073/pnas.162195499. Epub 2002 Jul 29. Proc Natl Acad Sci U S A. 2002. PMID: 12149459 Free PMC article.
-
Tetracyclines and prion infectivity.Infect Disord Drug Targets. 2009 Feb;9(1):23-30. doi: 10.2174/1871526510909010023. Infect Disord Drug Targets. 2009. PMID: 19200012
-
Evaluation of anti-prion activity of congo red and its derivatives in experimentally infected hamsters.Arzneimittelforschung. 2004;54(7):406-15. doi: 10.1055/s-0031-1296992. Arzneimittelforschung. 2004. PMID: 15344846
-
Prion encephalopathies of animals and humans.Dev Biol Stand. 1993;80:31-44. Dev Biol Stand. 1993. PMID: 8270114 Review.
-
Tetracycline repurposing in neurodegeneration: focus on Parkinson's disease.J Neural Transm (Vienna). 2018 Oct;125(10):1403-1415. doi: 10.1007/s00702-018-1913-1. Epub 2018 Aug 14. J Neural Transm (Vienna). 2018. PMID: 30109452 Review.
Cited by
-
Prions: Beyond a Single Protein.Clin Microbiol Rev. 2016 Jul;29(3):633-58. doi: 10.1128/CMR.00046-15. Clin Microbiol Rev. 2016. PMID: 27226089 Free PMC article. Review.
-
Application of an in vitro-amplification assay as a novel pre-screening test for compounds inhibiting the aggregation of prion protein scrapie.Sci Rep. 2016 Jul 7;6:28711. doi: 10.1038/srep28711. Sci Rep. 2016. PMID: 27385410 Free PMC article.
-
Doxycycline: An essential tool for Alzheimer's disease.Biomed Pharmacother. 2025 Jul;188:118159. doi: 10.1016/j.biopha.2025.118159. Epub 2025 May 13. Biomed Pharmacother. 2025. PMID: 40367557 Free PMC article. Review.
-
In vivo detection of prion amyloid plaques using [(11)C]BF-227 PET.Eur J Nucl Med Mol Imaging. 2010 May;37(5):934-41. doi: 10.1007/s00259-009-1314-7. Epub 2009 Dec 17. Eur J Nucl Med Mol Imaging. 2010. PMID: 20016895 Clinical Trial.
-
Combinatory FK506 and Minocycline Treatment Alleviates Prion-Induced Neurodegenerative Events via Caspase-Mediated MAPK-NRF2 Pathway.Int J Mol Sci. 2019 Mar 6;20(5):1144. doi: 10.3390/ijms20051144. Int J Mol Sci. 2019. PMID: 30845718 Free PMC article.
References
-
- Prusiner SB. Shattuck lecture–neurodegenerative diseases and prions. N Engl J Med. 2001;344:1516–1526. - PubMed
-
- Riesner D. Biochemistry and structure of PrP(C) and PrP(Sc). Br Med Bull. 2003;66:21–33. - PubMed
-
- Korth C, Peters PJ. Emerging pharmacotherapies for Creutzfeldt-Jakob disease. Arch Neurol. 2006;63:497–501. - PubMed
-
- Caramelli M, Ru G, Acutis P, Forloni G. Prion diseases: current understanding of epidemiology and pathogenesis, and therapeutic advances. CNS Drugs. 2006;20:15–28. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical